---

Development and validation of pimavanserin tartrate by normal phase- HPTLC method

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Mohammad Mojeeb Gulzar Khan*, Pawar Vivek Laxman, Abdul Talib, Sandip Dinkar Firke, Mohan G Kalaskar, Atul Arun Shirkhedkar

Volume : 8, Issue : 2, Year : 2021

Article Page : 75-78

https://doi.org/10.18231/j.ijpca.2021.015

Suggest article by email

Get Permission

Abstract

For the determination of pimvanserin tartrate in bulk and formulation, a rapid and simple High Performance Thin Layer Chromatography at 226 nm was developed and validated. The determination was carried out on thin coated aluminum backing plates covered with 200 mm layer of silica gel G 60 F254 (10×10 cm) plate as stationary phase and using a mobile phase of methanol: chloroform: trimethylamine (4:6:0.1 v/v/v) respectively. With a correlation coefficient (r) of 0.998, the development of pimvanserin tartrate was linear in the range of 0.7 to 4.2 µg/ml. The limit of detection (LOD) was found to be 7.68 ng/spot while the limit of quantification was found to be 23.28 ng/spot. The percentage label claim of pimvanserin tartrate in bulk and formulation was found to be 99 – 101 %. The percentage found in the formulation shows that no effect of excipient on drug. The conducted procedure has the benefit of being simple and quick. As a result, it can be used to examine pimvanserin tartrate in pharmaceutical formulations.

Keywords: HPTLC, Pimavanserin Tartrate, Bulk and tablet formulation, Validation

How to cite : Khan M M G, Laxman P V, Talib A, Firke S D, Kalaskar M G, Shirkhedkar A A, Development and validation of pimavanserin tartrate by normal phase- HPTLC method. Int J Pharm Chem Anal 2021;8(2):75-78

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.